Shares of Cell Genesys (CEGE) lost 8.3% following its earnings report after the close of trading on Thursday. The company reported quarterly revenue of $1.05 million compared with $2.78 million a year ago. Cell Genesys lost $27.9 million, or 60 cents a share, in the second quarter, compared with a loss of $27.4 million, or 60 cents a share, a year earlier. Analysts were expecting the company to lose 62 cents a share. The stock was recently trading at $4.54. Amgen (AMGN) fell a day after the company said a federal appeals court reversed a decision on two patent disputes with Transkaryotic Therapies. The federal court did affirm a lower court's decision that Transkaryotic and Aventis Pharmaceuticals infringed Amgen's patent on its anemia drug Epogen. Shares were down 3.1% to $68.73. Shares of Osteotech (OSTE) rose after the company said it swung to a profit for the second quarter. Osteotech earned $800,000, or 4 cents a share, compared with a loss of $1.9 million, or 11 cents a share, a year earlier. Revenue remained flat at $25.3 million. Shares were up 10.1% to $4.15. Adeza Biomedical (ADZA) , a maker of women's health products, gained 11.3% to $16.64 following its earnings report after the close of trading Thursday. For the second quarter, the company reported record sales of $13 million, up 23% from a year ago. Net income in the quarter reached $537,000, or 3 cents a share, including stock-based compensation expenses. Other health stocks on the move included Acorda Therapeutics (ACOR) , up 8.8% to $3.34, Immtech Pharmaceuticals (IMM) , gaining 7.4% to $5.78, Genentech (DNA) , rising 1.1% to $81.26, ViaCell (VIAC) , up 3.5% to $3.84, CuraGen (CRGN) , adding 3.9% to $3.17, and Oscient Pharmaceuticals (OSCI) , up 16.8% to $1.25. Novacea (NOVC) , shares took a 10.2% hit to $7.35, Orthologic's (OLGC) , shares fell 6.1% to $1.54, and CoTherix (CTRX) , was down 2.6% to $7.22.